Mydrane

Lidocaine hydrochloride, phenylephrine hydrochloride and tropicamide, the active ingredients in Mydrane, are local anesthetic and mydriatic agents presented as an intracameral solution for intra‑ocular use. It provides rapid pupil dilation and intra‑operative analgesia during cataract surgery in adult patients.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, surgical centres, ophthalmology clinics and procurement teams worldwide.

Mydrane is used in ophthalmic procedures that require rapid and sustained pupil dilation together with intra‑operative analgesia. - Cataract surgery: achieves quick mydriasis and reduces intra‑operative pain. - Anterior segment surgery: facilitates adequate pupil size for better surgical visualization. - Intra‑ocular procedures: provides analgesia and maintains dilation throughout the operation.

Mydrane may cause a range of ocular reactions, most of which are transient.

Common Side Effects: - Transient ocular discomfort or burning sensation. - Mild increase in intra‑ocular pressure. - Temporary blurred vision. - Conjunctival hyperemia. - Mild corneal edema. - Brief pupil irregularity.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Sustained elevation of intra‑ocular pressure. - Persistent mydriasis. - Corneal endothelial toxicity. - Endophthalmitis. - Retinal detachment (very rare).

Before using Mydrane, consider patient‑specific factors and handling requirements. - Allergy assessment: avoid in patients with known hypersensitivity to any component. - Intra‑ocular pressure: monitor patients with glaucoma or ocular hypertension. - Cardiovascular status: use caution in patients with uncontrolled hypertension due to phenylephrine. - Pediatric use: not recommended unless specifically prescribed by an ophthalmologist. - Corneal health: avoid in eyes with active corneal disease or compromised epithelium. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mydrane can interact with systemic and ocular agents that affect pupil size or vascular tone.

Major Interactions (Avoid): - Systemic phenylephrine with monoamine oxidase inhibitors or other sympathomimetics – risk of hypertensive crisis. - Concurrent use of other mydriatics – may cause excessive dilation. - Multiple local anesthetics – increased risk of lidocaine toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers – may diminish phenylephrine‑induced dilation. - Anticholinergic drugs – may potentiate tropicamide effects. - Other ophthalmic anti‑inflammatory agents – monitor for additive ocular irritation.